Arlington Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Arlington Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,263	Closed	-$200K	–	93
2024 Q3	$200K	Hold	4,263	–	–	0.04%	71
2024 Q2	$230K	Hold	4,263	–	–	0.05%	67
2024 Q1	$291K	Hold	4,263	–	–	0.06%	65
2023 Q4	$267K	Buy	+4,263	New	+$236K	0.08%	72
2023 Q3	–	Sell	-4,213	Closed	-$237K	–	60
2023 Q2	$237K	Buy	+4,213	New	+$239K	0.09%	53
2022 Q4	–	Sell	-3,113	Closed	-$203K	–	66
2022 Q3	$203K	Buy	+3,113	New	+$226K	0.1%	50
2022 Q1	–	Sell	-4,113	Closed	-$312K	–	58
2021 Q4	$312K	Buy	4,113 +1,010	+33%	+$88.2K	0.11%	63
2021 Q3	$347K	Buy	3,103 +40	+1%	+$5.02K	0.14%	48
2021 Q2	$496K	Hold	3,063	–	–	0.19%	47
2021 Q1	$373K	Buy	3,063 +63	+2%	+$9.51K	0.15%	48
2020 Q4	$459K	Buy	3,000 +150	+5%	+$17.7K	0.19%	50
2020 Q3	$238K	Buy	+2,850	New	+$253K	0.12%	51

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arlington Financial Advisors's CRSP Position: Q4 2024 in Review

Arlington Financial Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 4,263 shares — an estimated $200K sold.

Arlington Financial Advisors first reported a position in CRSP in Q3 2020 and held it in 12 quarters. The position peaked at $496K in Q2 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Arlington Financial Advisors reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Arlington Financial Advisors sold 4,263 CRISPR Therapeutics shares in Q4 2024, an estimated $200K.
Arlington Financial Advisors first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 12 quarters.
Arlington Financial Advisors's CRISPR Therapeutics position peaked at $496K in Q2 2021.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Arlington Financial Advisors's 13F filing for Q4 2024, filed 28 Jan 2025.